- Report
- July 2023
- 135 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- October 2023
- 181 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,031GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- June 2023
- 92 Pages
Europe
From €1441EUR$1,500USD£1,237GBP
- Report
- November 2018
- 106 Pages
Global
From €10564EUR$10,995USD£9,069GBP
- Report
- March 2024
- 77 Pages
Global
From €3500EUR$3,902USD£3,110GBP
The Opioid Agonist market is a subset of the Addiction Disorders Drugs market, which focuses on medications used to treat opioid addiction. These drugs are designed to reduce cravings and withdrawal symptoms, and to block the effects of other opioids. Commonly prescribed opioid agonists include methadone, buprenorphine, and naltrexone. These medications are used in combination with counseling and other forms of therapy to help individuals with opioid addiction achieve long-term recovery.
Opioid agonists are available in both generic and brand-name formulations. They are typically prescribed by a physician or other healthcare provider, and are available through pharmacies and other retail outlets.
Some companies in the Opioid Agonist market include Reckitt Benckiser, Purdue Pharma, Mallinckrodt Pharmaceuticals, and Mylan. Show Less Read more